Oncology

#AACR #AACR 2025 #Cancer #Cancer research #Cancer therapeutics #Oncology

Insight from AACR 2025

The American Association of Cancer Research (AACR) Annual Meeting took place from 25-30 April at the McCormick Place Convention Center in Chicago, US. DDW’s Megan Thomas looks at key announcements, presentations and breakthroughs that took place. Presidential commentary On Sunday 27 April, attendees were welcomed at the Opening Ceremony by… Read More

#Cancer Research #Exclusive Content

Subcutaneous injection
#Bristol Myers Squibb #Immunotherapy #NHS England #Oncology

NHS England rolls out injectable immunotherapy for 15 cancers

NHS England has become the first national health service in Europe to offer Bristol Myers Squibb’s injectable cancer immunotherapy nivolumab (Opdivo).  Nivolumab is a monoclonal antibody that binds to PD-1 (programmed death-1) on T-cells.  The jab can be used to treat 15 cancer types, including… Read More

#News

#AACR #Clasp Therapeutics #Oncology #Phase I trial #T cell engagers

First precision T-cell engager for solid tumours enters the clinic

Clasp Therapeutics has announced the dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumour-specific TCE to enter clinical development.   The company also presented non-clinical data for CLSP-1025 at the 2025 American Association for Cancer Research (AACR) Annual Meeting. … Read More

#Cancer Research #Editor's Choice #News

#AACR #Cancer research #Funding #Oncology

New $15 million cancer research grant launched at AACR

The AACR Trailblazer Cancer Research Grant Program, which was launched at the Annual Meeting Opening Ceremony, will award $15 million over three years.  It is designed for early-stage and mid-career investigators to support meritorious and promising cancer research.  “AACR has been a proud funder of… Read More

#Cancer Research #News

Biliary tract
#CHMP #European Medicines Agency #Jazz Pharmaceuticals #Oncology

CHMP issues positive opinion for biliary tract cancer treatment

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the conditional marketing authorisation of the EU’s first HER2-targeted therapy for biliary tract cancer (BTC).  Zanidatamab is an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody. … Read More

#News #Regulatory

#Clinical trials #Diabetes #Multiple sclerosis #Oncology #Phase II trial #Phase III trial

New DDW Highlights podcast: 28 April 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug… Read More

#News

Cancer cell
#Astex Pharmaceuticals #Combination therapy #Mosaic Therapeutics #Oncology

Mosaic in-licenses clinical-stage oncology assets from Astex

Mosaic Therapeutics has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical.  Mosaic has identified combinations incorporating the licensed products and their targets and the agreement gives Mosaic the exclusive rights to develop those combination products for patients for whom there are no,… Read More

#Business & Investment #Cancer Research #News

#Artificial intelligence (AI) #AstraZeneca #Foundational model #Oncology

Partners to build largest multimodal oncology foundation model

AstraZeneca, Tempus AI and Pathos AI have entered a multi-year, strategic collaboration to build a multimodal foundation model in oncology.  The model will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.  Upon completion,… Read More

#Business & Investment #Cancer Research #News

#Clinical trials #Diabetes #Multiple sclerosis #Oncology #Phase II trial #Phase III trial

This week in drug discovery (21-25 April) 

News round-up for 21-25 April by DDW Senior Digital Content Editor Diana Spencer. With Eli Lilly so far winning the race to bring an oral GLP-1 drug to market, having announced positive topline results from a Phase III trial, this week our news highlights focus on clinical studies. Read More

#News

Tumour microenvironment
#Collaboration #Genetics / genomics #Oncology #Solid tumours

AACR data shows promise for patients with solid tumour types

Data from the Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR), demonstrate a strong association between changes in levels of circulating tumour DNA (ctDNA) and treatment outcomes. This offers the potential for integration of ctDNA analysis in therapeutic development programmes, and clinical cancer… Read More

#Cancer Research #News

Chinese flag
#Ascentage Pharma #Blood cancer #China #Haematology #Oncology

Ascentage celebrates inclusion in Chinese oncology guidelines

Two of Ascentage Pharma’s drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.   Lisaftoclax (APG-2575), an investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies.  This makes… Read More

#News

Melanoma
#Aulos Bioscience #Melanoma #Monoclonal antibodies #Oncology #Phase II trial

Aulos doses first patient in Phase II cohort for melanoma treatment

Aulos Bioscience has dosed its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma.   The new cohort forms part of the company’s Phase I/II clinical trial of AU-007… Read More

#Cancer Research #News

Non-small cell lung cancer
#Candel Therapeutics #Immunotherapy #Lung cancer #Oncology #Phase II trial

Unique immunotherapy extends survival in advanced NSCLC

Candel Therapeutics’ CAN-2409 has demonstrated a median overall survival (mOS) of 24.5 months in a Phase IIa clinical trial in patients with stage III/IV non-small cell lung cancer (NSCLC).  The 46 evaluable patients, who are nonresponsive to immune checkpoint inhibitor (ICI) treatment, received two courses of CAN-2409. Read More

#Cancer Research #Editor's Choice #News

#3D modelling #Artificial intelligence (AI) #European Commission #Monoclonal antibodies #Oncology #Solid tumours

This week in drug discovery (7-11 April) 

News round-up for 7-11 April by DDW Senior Digital Content Editor Diana Spencer. As the political news brings more uncertainty for the sector, this week we are focusing on positive developments in the field of oncology, from the possibilities of cancer cures in the rainforest, to a new… Read More

#News